An Open-label, Multi-center, International, Three-year, Safety and Tolerability 'Follow on' Trial
Recruiting in Palo Alto (17 mi)
+38 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: Mannkind Corporation
No Placebo Group
Prior Safety Data
Trial Summary
What is the purpose of this trial?
Safety Follow-Up Trial to PDC-INS-0008 and MKC-TI-005
Research Team
AB
Anders Boss, MD
Principal Investigator
Mannkind Corporation
Eligibility Criteria
Inclusion Criteria
Previous completion of PDC-INS-0008 or MKC-TI-005
Subjects must be able to attend all scheduled visits and, in the opinion of the Investigator, be able to complete this safety trial
Subjects must be able to understand English or have access to validated primary language trial documents
See 1 more
Treatment Details
Interventions
- Technosphere® Insulin Inhalation Powder (Insulin)
Participant Groups
1Treatment groups
Experimental Treatment
Group I: TI Inhalation PowderExperimental Treatment1 Intervention
Technosphere® Insulin Inhalation Powder
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mannkind Corporation
Lead Sponsor
Trials
61
Recruited
8,400+
Michael E. Castagna
Mannkind Corporation
Chief Executive Officer since 2017
PharmD from Massachusetts College of Pharmacy & Sciences, MBA from The Wharton School of Business at the University of Pennsylvania
Burkhard Blank
Mannkind Corporation
Chief Medical Officer since 2021
MD